Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IMMCEPTION 2

Financiado

Cerrado

Development of a new therapeutic product targeting neuroimmune circuits to treat...

Development of a new therapeutic product targeting neuroimmune circuits to treat asthma Asthma affects approximately 3% of the population and results in 1,000 daily deaths. It is characterized by chronic lung inflammation and airway hyperresponsiveness. First lines of treatment have not evolved in the last decades an... ver más

28/02/2026

INSERM

Presupuesto desconocido

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-09-01

ERC-2024-POC: ERC PROOF OF CONCEPT GRANTS Objective:ObjectivesThe ERC Proof of Concept Grants aim at facilitating exploration of the commercia...

I+D

Cerrada hace 10 meses

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

INSERM

Lider

Proyectos interesantes

JCI-2011-09924

Medical Technol...

Applied Physics

96K€ Cerrado

PTQ-11-04394

Medical Technol...

Pharmaceutical...

53K€ Cerrado

DISEÑO MOLECULAR Y SÍNTESIS DE MOLÉCULAS PARA...

Medical Technol...

Pharmaceutical...

3M€ Cerrado

TSLP IN ASTHMA

Medical Technol...

Pharmaceutical...

139K€ Cerrado

DESCUBRIMIENTO Y DESARROLLO DE NUEVOS ACTIVAD...

Medical Technol...

Pharmaceutical...

Rechazado

Novel asthma therapy

Medical Technol...

Nanotechnology

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 17 meses Fecha Inicio: 2024-09-01
Fecha Fin: 2026-02-28

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Asthma affects approximately 3% of the population and results in 1,000 daily deaths. It is characterized by chronic lung inflammation and airway hyperresponsiveness. First lines of treatment have not evolved in the last decades and actual developments are essentially focusing on severe asthma management (7% of patients) via the targeting of inflammatory mediators. Unfortunately, 60% of asthmatics still suffer from uncontrolled symptoms.The lungs are innervated by peripheral neurons expressing specific sets of G protein-coupled receptors (GPCR) that contribute to bronchoconstriction and regulate allergic immune response. Among the broad family of GPCRs, the GPCRX has never been studied in a pathological context, albeit human and murine orthologs share a remarkable sequence identity. We have created a new transgenic mouse, GPCRXMut, allowing both to track the receptor expression and to interrogate its function in vivo. The GPCRXMut mouse exhibits normal immune and sensory systems at steady state. Our data demonstrate that a) GPCRX is expressed by both peripheral neurons and certain lung-resident immune cells; b) the selective invalidation of GPCRX completely protects against the development of asthma in various models; and c) lung biopsies from asthmatic patients show high expression of GPCRX in neurons and immune cells.The ERC proof of concept project IMMCEPTION 2 aims to develop a selective antagonist for GPCRX to treat asthmatic patients. We will 1) miniaturize our established screening system for antagonists; 2) identify leads capable of specifically blocking GPCRX; and 3) develop a new mouse model humanized for the GPCRX to further validate identified leads in vivo. The research program has been carefully designed to leverage our expertise in neurobiology, immunology, asthma, and clinical allergy and has the potential to lead to the development of a new oral molecule with a dual mode of action to silence lung neuroimmune circuits.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores